Abbott Laboratories (ABT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Abbott Laboratories.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 105.70 $ — 43% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 12.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 27
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5.52 | 5.48 – 5.56 | 50,304 | 7.1% | 25 |
| 12/31/2027 | 6.06 | 5.88 – 6.20 | 54,649 | 9.9% | 25 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.42 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 5.29 | 479.60 | 10,974 | 7.20 | 84.10 | 2,868 | 2,148 |
| 2025: Q1 | 0.76 | 8.30 | 10,358 | 4.00 | 12.80 | 1,417 | 933 |
| 2025: Q2 | 1.02 | 36.60 | 11,142 | 7.40 | 16.00 | 2,047 | 1,545 |
| 2025: Q3 | 0.94 | -0.20 | 11,369 | 6.90 | 14.50 | 2,787 | 2,291 |
| 2025: Q4 | 1.02 | -80.80 | 11,459 | 4.40 | 15.50 | 3,315 | 2,626 |
| 2026: Q1 | 0.62 | -18.70 | 11,164 | 7.80 | 9.60 | 1,315 | 916 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 20,853 | 3,249 | 1,400 | 0.94 | 3,203 | 20,538 | 55,011 |
| 2017 | 27,390 | 1,972 | 477 | 0.27 | 5,570 | 30,897 | 76,250 |
| 2018 | 30,578 | 3,844 | 2,368 | 1.34 | 6,300 | 30,524 | 67,173 |
| 2019 | 31,904 | 4,591 | 3,687 | 2.07 | 6,136 | 31,088 | 67,887 |
| 2020 | 34,608 | 5,291 | 4,495 | 2.52 | 7,901 | 32,784 | 72,548 |
| 2021 | 43,075 | 9,200 | 7,071 | 3.95 | 10,533 | 35,802 | 75,196 |
| 2022 | 43,653 | 8,362 | 6,933 | 3.93 | 9,581 | 36,686 | 74,438 |
| 2023 | 40,109 | 6,435 | 5,723 | 3.27 | 7,261 | 38,603 | 73,214 |
| 2024 | 41,950 | 6,825 | 13,402 | 7.67 | 8,558 | 47,664 | 81,414 |
| 2025 | 44,328 | 8,048 | 6,524 | 3.73 | 9,566 | 52,130 | 86,713 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Abbott Laboratories erforscht, entwickelt, fertigt und verkauft mit ihren Tochtergesellschaften weltweit Gesundheitsprodukte. Sie ist in vier Segmenten tätig: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products und Medical Devices.
| Employees | 122,000 |
|---|---|
| Headquarters | Abbott Park, IL |
| Address | 100 Abbott Park Road, 60064-6400 Abbott Park, United States |
| Phone | 224 667 6100 |
| Website | abbott.com |
| IPO Date | 13. Jan 1978 |
| ISIN | US0028241000 |
| Stock Split | 10000:4798 on 01/02/2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Philip P. Boudreau | CFO & Executive VP of Finance | 1973 |
| Daniel Gesua Sive Salvadori | Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 1979 |
| Christopher J. Scoggins | Executive Vice President of Diabetes Care | 1970 |
| Lisa D. Earnhardt | Executive VP & Group President of Medical Devices | 1970 |
| Sabina Ewing | Senior VP of Business & Technology Services and Chief Information Officer | 1974 |
| Michael Comilla | Vice President of Investor Relations. | – |
| Erica L. Battaglia | VP and Chief Ethics & Compliance Officer | – |
| Elizabeth C. Cushman | Executive VP, General Counsel & Secretary | 1970 |
| Melissa Brotz | Senior Vice President of Global Marketing & External Affairs | – |
| Mary K. Moreland | Executive Vice President of Human Resources | 1966 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.